Sigrid Therapeutics stock
Sigrid Therapeutics is a Swedish clinical biotechnology company developing innovative solutions to prevent and treat lifestyle-related diseases. The company was founded in 2014 by Prof. Tore Bengtsson and Sana Alajmovic with the vision to change the way we manage modern chronic diseases. Their technology, SiPore®, consists of precision-engineered mesoporous silica particles that act in the gut to improve blood sugar control in a safe and effective way. The lead product, SiPore21®, is an oral medical device in clinical development, intended to improve metabolic function in people with prediabetes and new-onset type 2 diabetes. Sigrid Therapeutics is headquartered in Stockholm and is part of Karolinska Innovation's incubator program for promising life science startups in Sweden.
Sigrid Therapeutics share price
Current bids and asks, the latest trade and Sigrid Therapeutics's valuation. The full price history opens once you create an account.
Account required
See the full price history
Complete transaction history, order depth and valuation data are free once you open an account.
Create accountOther companies you may be interested in
Note: Share price is from each company's latest known share issue. The change compares it with the previous issue and does not account for splits or differing share classes.
Sigrid Therapeutics new issues and valuations
| Date | Type | Share price | Valuation The company's valuation after the funding round was completed (Post-money). | Amount The specific amount raised in this funding round. |
|---|---|---|---|---|
| Q1 2026 | Share issuance | 23.39 SEK | SEK 594,836,283 | Locked |
| Q4 2025 | Share issuance | 23.39 SEK | SEK 586,327,702 | Locked |
| Q4 2023 | Share issuance | 20.6 SEK | SEK 476,972,915 | Locked |
See the amount raised in every funding round
Free · about two minutes
Note: Information on Sigrid Therapeutics's funding rounds, amounts, and valuation is sourced from news media and public sources unless otherwise stated. Information on capital structure is sourced from public company registers unless otherwise stated.
Buy or sell Sigrid Therapeutics shares
Place a bid or a sell order. Accumeo matches you with the counterparty and handles the transfer through an established process.
Create accountFree · about two minutes
Have questions about the platform or how a trade in Sigrid Therapeutics works? Our transaction team is available and happy to help.
Book a callReply within one business day
Have any questions about buying or selling shares in private companies? Don't hesitate to contact us.
How trading works
From account to completed transfer
1. Create an account
Identification is handled with BankID. The account is free and carries no obligation to trade.
2. Study the company
Price history, completed trades, ownership and documents gathered in one place.
3. Place your order
State the number of shares, the price and any conditions. Your order is anonymous to the market.
4. We handle settlement
On a match we draw up a share transfer agreement covering price, share count and closing date.
Settlement follows an established process with third-party verification of payment and share transfer, minimizing counterparty risk for both parties.
What an account unlocks
Every completed transaction in Sigrid Therapeutics, with date and price per share.
The order book's price picture, updated in real time.
Largest owners, annual reports and issue terms.
A notice when new interest is registered or the price moves.
Sigrid Therapeutics is a Swedish clinical biotechnology company developing innovative solutions to prevent and treat lifestyle-related diseases. The company was founded in 2014 by Prof. Tore Bengtsson and Sana Alajmovic with the vision to change the way we manage modern chronic diseases. Their technology, SiPore®, consists of precision-engineered mesoporous silica particles that act in the gut to improve blood sugar control in a safe and effective way. The lead product, SiPore21®, is an oral medical device in clinical development, intended to improve metabolic function in people with prediabetes and new-onset type 2 diabetes. Sigrid Therapeutics is headquartered in Stockholm and is part of Karolinska Innovation's incubator program for promising life science startups in Sweden.
Note: Information on Sigrid Therapeutics is sourced from official channels and public sources unless otherwise stated.
Major Shareholders in Sigrid Therapeutics
| Owner | Share |
|---|---|
| Ulf Wiinberg consult&invest AB | 21.56 % |
| M.G.A. Holding Aktiebolag | 8.46 % |
| THE BANK OF NEW YORK MELLON SA/NV, W8IMY | 4.00 % |
| Opis Luma AB | 3.51 % |
| SIX SIS AG, W8IMY | 3.36 % |
Source: Eivora (6/30/2026) · Information on Sigrid Therapeutics's ownership structure is sourced from public company registers and external data providers unless otherwise stated.
Sigrid Therapeutics key figures
| Key figures (SEK) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Income statement | |||
| Net sales | 12,841,000 | 1,717,000 | 0 |
| Operating result (EBIT) | -22,163,000 | -44,355,000 | -31,523,000 |
| EBITDA | -21,426,000 | -43,618,000 | -30,932,000 |
| Net profit for the year | -22,131,000 | -43,107,000 | -30,607,000 |
| Balance sheet | |||
| Total assets | 45,518,000 | 35,409,000 | 73,432,000 |
| Cash and bank | 18,130,000 | 22,023,000 | 62,473,000 |
| Current liabilities | 9,958,000 | 13,924,000 | 9,684,000 |
| Ratios | |||
| EBITDA margin | -163.0 % | -2,438.1 % | -2,437.5 % |
| Equity ratio | 78.1 % | 60.7 % | 86.8 % |
| Employees | 7 | 7 | 7 |
Figures come from the company's filed annual reports.
Sigrid Therapeutics documents
Interested in Sigrid Therapeutics shares?
Create an account to see completed trades and order depth, or call us if you would rather talk through the price picture first.
News about Sigrid Therapeutics
Sigrid Therapeutics Launches on Fullscript, Expanding U.S. Practitioner Access
Sigrid Therapeutics announced the launch of its practitioner portfolio on Fullscript, a North American healthcare practitioner platform, expanding access to its SiPore® technology. This partnership allows practitioners to tailor the use of SiPore® technology to different patient needs and clinical protocols.
SiPore® Practitioner Portfolio Now Available on Fullscript, Expanding Access to Gut-Local Metabolic Health Solutions Across the United States
Sigrid Therapeutics announced that its practitioner portfolio, including SiPore® Capsules and SiPore® Liquid, is now available on Fullscript, expanding access to their gut-local metabolic health solutions across the United States.
Sigrid Therapeutics nya vd på plats: Fokus på kommersiell uppskalning
Utnämningen, som offentliggjordes i slutet av januari, var en tydlig signal från Sigrids styrelse. Genom att rekrytera en ledare med djupa rötter i både snabbrörliga konsumentvaror (FMCG) och läkemedelsindustrin, siktar bolaget på att ta marknadsandelar inom den växande nischen för metabol hälsa med sin egenutvecklade SiPore-teknologi. En flygande start Kjærsgaard klev in i Sigrid i […]
Sigrid Therapeutics ingår globalt licensavtal inom munhälsa
Sigrid Therapeutics har ingått ett exklusivt globalt licens- och forskningssamarbete med ett ledande multinationellt konsumenthälsoföretag för att kommersialisera SiPore-teknologin inom konsumentinriktad munhälsa. Avtalet berättigar Sigrid till en förskottsbetalning samt framtida ersättningar kopplade till utvecklingsmål, kliniska framsteg och försäljningsmilstolpar, utöver löpande royalties på nettoförsäljning. Samarbetet etablerar ett ramverk för gemensam forskning och klinisk utvärdering med målet […]
Ozempic-utmanaren Sigrid Therapeutics backas med 45 miljoner – ska växa i USA
Svenska Sigrid Therapeutics får in 45 miljoner kronor för att få spinn på sitt kosttillskott och lansera sin Ozempic-utmanare “Carb fence”.
Sana Alajmovic lämnar som VD för Sigrid Therapeutics i början av 2026
Stockholm, 12 augusti 2025 – Sigrid Therapeutics AB (Sigrid) meddelar att VD Sana Alajmovic lämnar sin operativa roll den 31 januari 2026 för att tillträda en ny befattning utanför Sigrids verksamhet och som inte konkurrerar med bolaget. Sanas beslut kommer i en period av stark tillväxt för Sigrid, efter lanseringen av Glucose Stabiliser, avslutningen av SHINE – en av världens största kliniska studier inom prediabetes – samt intensifierade partnerskapsdiskussioner inför internationell lansering. – Genom sitt visionära ledarskap och sitt hårda arbete har Sana lagt grunden för Sigrids nästa
Sigrid Therapeutics säkrar marknadsgodkännande i USA för SiPore-teknologi efter framgångrik SHINE prediabetesstudie
Sigrid Therapeutics (Sigrid) meddelar idag att de har säkrat marknadsgodkännande i USA för sin patenterade SiPore-teknologi, efter den framgångsrika SHINE-studien vilket är den största studien av sitt slag inom prediabetes.
Sigrid Therapeutics överträffar 50% rekrytering av patienter i sin kliniska studie, SHINE, där SiPore21® utvärderas för hållbar diabetes- och fetmakontroll
· SHINE är den hittills största pågående kliniska studien av sitt slag och utgör en milstolpe inom forskningen om prediabetes och viktkontroll. Den inkluderar patienter som lever med övervikt eller fetma och har prediabetes eller icke-medicinerad typ 2-diabetes. · SiPore21® Silica "Molecular Sieves" är ett lovande, icke-farmaceutiskt oralt alternativ till injicerbara läkemedel för hållbar viktkontroll. Stockholm, 30 april 2024: Sigrid Therapeutics meddelade idag att bolaget har rekryterat över 50% av patienterna i SHINE, en klinisk studie som utvärderar SiPore21® för behandling av
Sigrid Therapeutics säkrar 44 MSEK i övertecknad finansieringsrunda med sikte på den växande marknaden för behandling av fetma och diabetes
Sigrids naturliga, receptfria SiPore-teknologi® attraherade både nordiska och internationella investerare. Stockholm, 31 oktober 2023. Sigrid Therapeutics har säkrat 44 miljoner kronor i en framgångsrik och övertecknad finansieringsrunda, något som understryker investerarnas starka förtroende för Sigrids innovativa SiPore-teknologi®. Såväl befintliga som nya investerare deltog. Kapitaltillskottet är viktigt för att accelerera kommersialiseringen av SiPore® på olika marknader. Sigrid ska nu lansera SiPore® för behandling av fetma och diabetes som medicinteknisk produkt, som kosttillskott
FAQ
Sigrid Therapeutics has raised a total of SEK 252 million in capital, according to our records. The amount raised in each funding round is shown once you create an account.
In its latest share issue, in January 2026, Sigrid Therapeutics was valued at SEK 595 million post-money. The price was SEK 23.39 per share.
The largest shareholders in Sigrid Therapeutics are Ulf Wiinberg consult&invest AB (21.56 %), M.G.A. Holding Aktiebolag (8.46 %), and THE BANK OF NEW YORK MELLON SA/NV, W8IMY (4.00 %). The figures come from Eivora and were last updated in June 2026.
In 2025, Sigrid Therapeutics had revenue of SEK 12.8 million. It reported a loss of SEK 22.1 million for the year.
The CEO of Sigrid Therapeutics is Claus Kjaersgaard. The board is chaired by Mattias Ankarberg.
Sigrid Therapeutics is an unlisted company, meaning the shares are not traded on any exchange. Instead, transactions take place through direct transfers between parties, known as secondary trading, typically via a specialised platform for unlisted shares such as Accumeo. For larger international companies, investing through fund structures that pool several investors into a single ownership vehicle is also common. This allows smaller minimum investments and opens up access to international companies for non-institutional investors.
Yes, it is possible to buy existing shares in Sigrid Therapeutics through secondary trading. On Accumeo you create a free account, submit an expression of interest with an amount and any conditions, and may then be matched with a seller. Once both parties have signed the customer agreement, a share transfer agreement is drawn up covering price, share count, and settlement date.
Yes, secondary trading is often the only realistic route to liquidity for an unlisted holding before an IPO or acquisition. Via Accumeo you submit an expression of interest with a share count and target price, and a match may be made with a potential buyer. The sale is executed through a share transfer agreement and registered either via Euroclear or directly in the company's share register, depending on how ownership is administered.
Unlisted companies have no continuous share price because there is no continuous exchange trading. The value is instead based on the latest secondary-market trade or on the price per share from the most recent share issuance. Accumeo shows both historical transaction prices and current bid/ask quotes, providing a combined reference point for pricing.
The value of an unlisted share is most often based on the latest trade — the price buyer and seller agreed in a transaction — or on the latest funding round, where the company and its investors agreed a price for the newly issued shares. These are the reference points shown on Accumeo's platform. It is, however, important to form your own view of value by examining the company's prospects. Financial reports, growth opportunities, market position, and comparable transactions in the sector all help to build a better picture of how the business may develop. Useful information can be found on the company's own website, via Accumeo's platform, and on services like allabolag.se.
No, Sigrid Therapeutics is an unlisted company and its shares are not traded on the Stockholm Stock Exchange, NYSE, or any other regulated marketplace. Shares are instead traded through secondary trading between investors, typically via a specialised platform such as Accumeo.
Yes. Shares in Sigrid Therapeutics can be delivered to an ordinary securities account with a broker such as Avanza or Nordnet, and are registered as the transaction completes.
Yes. The articles of association carry transfer restrictions, giving existing shareholders the right to take over the shares ahead of an outside buyer. Expect the transfer to take around 30 days longer while that runs its course.
Disclaimer: The information in this FAQ is provided for informational purposes only and does not constitute an offer to buy or sell securities, a solicitation of such an offer, or investment advice. Accumeo has no commercial relationship with the companies whose securities are mentioned. Independent advice should be obtained before making any investment decision.
Start exploring unlisted shares today
Join 5,000+ investors already trading unlisted shares. Create an account in 2 minutes with BankID — completely free.